Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Decibel Cannabis Company (DBCCF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Decibel Cannabis Company $0.17, price $1.18, upside -85.6%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
DC
Thin data
Sep 24, 2026
Thin data
Sep 24, 2026
Decibel Cannabis Company
DBCCF · USWeakest SetupStrongly overvalued and low quality.
!Fair value $0.1700 · Strongly overvalued (−85.6%)
!Quality 41/100
!Mixed Growth (revenue 5y +30.4 %/yr)
!Loss-making · -2.6% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 22/100
!Evidence only low, so the estimate is less certain
!The models disagree: range $0.0900 to $0.3200
Watch Decibel Cannabis Company for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.0002 – $4.24 · fair‑value band $0.0900 – $0.3200 · the $1.18 price screens above the $0.1700 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Decibel Cannabis Company Inc., an integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada. It is also involved in the extraction, processing, and manufacturing of cannabis derivative products, including vapes, cannabis infused pre-rolls, pre-rolls, edibles, and other value added products.
Show more
Decibel Cannabis Company Inc., an integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada. It is also involved in the extraction, processing, and manufacturing of cannabis derivative products, including vapes, cannabis infused pre-rolls, pre-rolls, edibles, and other value added products. The company also engages in the business-to-business cannabis product sales in the provinces of Saskatchewan and Alberta; and e-commerce end-user customers in the province of Saskatchewan. It offers its products under the Qwest, Vox, Blendcraft, and General Admission brands. Decibel Cannabis Company Inc. is headquartered in Calgary, Canada.
Stock analysis
Decibel Cannabis Company (DBCCF) currently trades at $1.18, while our model-based Fair Value estimate is $0.1700, 85.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $0.1400 per share, and 0 of the 10 models we run sit above the $1.18 price.
Bear case: the Growth DCF group reads lowest at $0.0400, and 10 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0900 (bear) to $0.3200 (bull), the price of $1.18 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Decibel Cannabis Company reported revenue of C$113M in FY2025 versus C$52.5M in FY2021, a compound +21.1%/yr. Reported net income was −C$2.9M in FY2025.
Key figures
Market cap $49.0M · P/S ratio 0.40 · EPS (TTM) $−0.0100 · Net margin −2.6% · Return on equity −5.2% · Return on assets (EBIT) 2.0% · Operating margin 9.6% · Revenue (TTM) $121M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 28% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −86%, DBCCF screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.0300 to $0.2500). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $0.0900
Fair Value $0.1700
Bull $0.3200
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$0.1300
$0.2100
$0.4600
75
Growth DCF
$0.1200
$0.2500
$0.4500
75
5Y Revenue Exit
$0.0200
$0.0300
$0.0500
71
All 10 models by family
DCF Models
FCF DCF
$0.1300
$0.2100
$0.4600
75
Owner Earnings
$0.0500
$0.1400
$0.3200
69
5Y Revenue Exit
$0.0200
$0.0300
$0.0500
71
5Y EBITDA Exit
$0.0900
$0.1600
$0.3100
71
10Y Revenue Exit
$0.0600
$0.1000
$0.1000
68
10Y EBITDA Exit
$0.1000
$0.2300
$0.4400
64
Multiples
EV/EBITDA
$0.0700
$0.0900
$0.1200
67
Asset-Based
NCAV (Graham)
$0.0400
$0.0500
$0.0800
53
Growth DCF
Growth DCF
$0.1200
$0.2500
$0.4500
75
Rev-Margin DCF
$0.0300
$0.0400
$0.0800
69
Notify me when DBCCF reaches fair value
Put DBCCF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
41/100
Of which business quality 40 · Market factors (momentum, volatility) 33
Profitability
25
Margins and returns on capital today
Quality Growth
40
Are margins and returns improving?
Cashflow
43
Earnings quality: real cash, not paper profit
Fin. Strength
31
Balance sheet, leverage, solvency risk
Investment
84
Disciplined investing over empire-building
Low Volatility
50
Calm price path (market factor)
Momentum
28
Price trend over the last 3–12 months (market factor)
52W Momentum
21
Distance to the 52-week high (market factor)
Net Issuance
40
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+21.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.4%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.0%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−18.1% (2020) → 0.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+42.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +38.9% a year for the price and +8.0% for the forecasts.
Forecast 2026 (sales)+17.7%
Forecast 2027 (sales)+10.4%
Projected 2028 (sales)+9.4%
Projected 2029 (sales)+8.3%
Projected 2030 (sales)+7.3%
DBCCF screens overvalued: fair value 86% below the price. Compare with Merck KGaA →
Compare Decibel Cannabis Company with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €134.45 | €108.94 | −19% |
| Takeda Pharmaceutical Company TAK | $18.90 | $11.45 | −39% |
| Teva Pharmaceutical Industries Limited TEVA | $39.31 | $20.88 | −47% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,852 | ₹1,979 | +7% |
| Galderma Group GALD | CHF 163.00 | CHF 110.32 | −32% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥44.86 | ¥49.35 | +10% |
| Haleon plc HLN | $9.26 | $8.49 | −8% |
| Sandoz Group SDZ | CHF 71.16 | CHF 40.32 | −43% |
| Zoetis Inc ZTS | $70.30 | $110.50 | +57% |
| Divi's Laboratories Limited DIVISLAB | ₹9,620 | ₹1,871 | −81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Decibel Cannabis Company (DBCCF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.1700 versus a price of $1.18, about −86% upside (overvalued).
What is the fair value of DBCCF?
Our model-based fair value for Decibel Cannabis Company is $0.1700 (as of Sep 24, 2026), built from audited fundamentals. The current price: $1.18.
What is the quality score of DBCCF?
Decibel Cannabis Company has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Decibel Cannabis Company (DBCCF)?
Our model-based price target is the fair value of $0.1700 (as of Sep 24, 2026) from 10 valuation models. Cautious scenario $0.0900, optimistic scenario $0.3200. It is a calculation from audited fundamentals, not an analyst target.
What is the Decibel Cannabis Company stock forecast for 2026?
Our models put fair value at $0.1700, about −86% upside versus a price of $1.18 (overvalued). Cautious scenario $0.0900, optimistic scenario $0.3200. The calculation is refreshed regularly with new filings.
What is the revenue of Decibel Cannabis Company (DBCCF)?
Decibel Cannabis Company reported trailing-twelve-month revenue of about $121M (latest available figure, as of Sep 24, 2026).
What growth is priced into Decibel Cannabis Company (DBCCF)?
For today's price to be fair in a discounted-cash-flow model, Decibel Cannabis Company would have to grow free cash flow by +42.2 % per year for five years (discount rate 8.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +30.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of DBCCF use?
Our models discount Decibel Cannabis Company at 8.5 %: a base by market capitalisation (nano), damped by beta 0.49, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Decibel Cannabis Company that is +42.2 % per year a year over ten years, using the same discount rate (8.5 %) and the same formula as our fair value.
How much growth has Decibel Cannabis Company (DBCCF) delivered so far?
Over the past 5 years revenue at Decibel Cannabis Company grew +30.4 % a year. The price currently implies +42.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Decibel Cannabis Company (DBCCF) growing?
The median revenue growth in the sector is +5.0 % a year. That is the yardstick for the growth priced into Decibel Cannabis Company (+42.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Decibel Cannabis Company (DBCCF)?
The free-cash-flow yield on the price is 0.80 %: that much free cash flow Decibel Cannabis Company produces per unit of market value. When it exceeds the discount rate of our models (8.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Decibel Cannabis Company (DBCCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Decibel Cannabis Company it is $0.1700 per share (as of Sep 24, 2026), against a price of $1.18. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Decibel Cannabis Company stock overvalued or undervalued in 2026?
As of Sep 24, 2026, DBCCF trades above its calculated fair value: price $1.18, fair value $0.1700, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DBCCF?
No. The price is what the market pays today ($1.18); the fair value is what the company's own numbers justify ($0.1700). For Decibel Cannabis Company the two are $1.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Decibel Cannabis Company worth?
The market values Decibel Cannabis Company at about $49.0M (market capitalisation, as of Sep 24, 2026). Per share that is $1.18; our models calculate a fair value of $0.1700 per share.
What do the bullish and bearish scenarios say about DBCCF?
Our models span a range for Decibel Cannabis Company: cautious scenario $0.0900, base $0.1700, optimistic $0.3200 per share (as of Sep 24, 2026, price $1.18). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Decibel Cannabis Company (DBCCF)?
Balance-sheet figures for Decibel Cannabis Company (as of Sep 24, 2026): return on equity −5.2%, debt of 0.42 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is DBCCF from its 52-week high?
Decibel Cannabis Company trades at $1.18, about 28% below its 52-week high of $1.64 and 21% above the low of $0.9765 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1700 is for.
Which stocks are comparable to Decibel Cannabis Company?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Decibel Cannabis Company stock attractive at the current price?
The data as of Sep 24, 2026: price $1.18, calculated fair value $0.1700 (−86%), Quality Score 41/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DBCCF calculated?
We run Decibel Cannabis Company through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Decibel Cannabis Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Decibel Cannabis Company (DBCCF)?
The closing price on Oct 2, 2026 was $1.18. Our model-based fair value is $0.1700, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Decibel Cannabis Company right now?
The price sits above even our optimistic bull case ($0.3200). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($0.0900 to $0.3200). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Decibel Cannabis Company
How large is the market capitalisation of Decibel Cannabis Company (DBCCF)?
The market capitalisation of Decibel Cannabis Company is $49.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Decibel Cannabis Company (DBCCF)?
The price-to-sales ratio of Decibel Cannabis Company is 0.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Decibel Cannabis Company (DBCCF)?
Earnings per share at Decibel Cannabis Company are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Decibel Cannabis Company (DBCCF)?
The net margin of Decibel Cannabis Company is −2.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Decibel Cannabis Company (DBCCF)?
The return on equity (ROE) of Decibel Cannabis Company is −5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Decibel Cannabis Company (DBCCF)?
On an EBIT basis the return on assets of Decibel Cannabis Company is 2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Decibel Cannabis Company (DBCCF)?
The operating margin of Decibel Cannabis Company is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Decibel Cannabis Company (DBCCF)?
Revenue at Decibel Cannabis Company is growing +40.5% versus a year earlier (3y avg +12.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Decibel Cannabis Company (DBCCF)?
Earnings per share at Decibel Cannabis Company are growing +880% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Decibel Cannabis Company (DBCCF) carry?
The net debt of Decibel Cannabis Company is $27.8M (fiscal year 2025, ≈ 5.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Decibel Cannabis Company in the live analysis
One click puts Decibel Cannabis Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.